These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31508899)

  • 1. Population Pharmacokinetic Analysis for Imipenem-Relebactam in Healthy Volunteers and Patients With Bacterial Infections.
    Bhagunde P; Patel P; Lala M; Watson K; Copalu W; Xu M; Kulkarni P; Young K; Rizk ML
    CPT Pharmacometrics Syst Pharmacol; 2019 Oct; 8(10):748-758. PubMed ID: 31508899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam.
    Bhagunde P; Zhang Z; Racine F; Carr D; Wu J; Young K; Rizk ML
    Int J Infect Dis; 2019 Dec; 89():55-61. PubMed ID: 31479762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase 1b, Open-Label, Single-Dose Clinical Trial.
    Bradley JS; Makieieva N; Tøndel C; Roilides E; Kelly MS; Patel M; Vaddady P; Maniar A; Zhang Y; Paschke A; Chen LF
    J Clin Pharmacol; 2023 Dec; 63(12):1387-1397. PubMed ID: 37562063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imipenem/relebactam pharmacokinetics in critically ill patients supported on extracorporeal membrane oxygenation.
    Fratoni AJ; Kois AK; Gluck JA; Nicolau DP; Kuti JL
    J Antimicrob Chemother; 2024 May; 79(5):1118-1125. PubMed ID: 38517465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
    Sims M; Mariyanovski V; McLeroth P; Akers W; Lee YC; Brown ML; Du J; Pedley A; Kartsonis NA; Paschke A
    J Antimicrob Chemother; 2017 Sep; 72(9):2616-2626. PubMed ID: 28575389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects.
    Rizk ML; Rhee EG; Jumes PA; Gotfried MH; Zhao T; Mangin E; Bi S; Chavez-Eng CM; Zhang Z; Butterton JR
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.
    Lucasti C; Vasile L; Sandesc D; Venskutonis D; McLeroth P; Lala M; Rizk ML; Brown ML; Losada MC; Pedley A; Kartsonis NA; Paschke A
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6234-43. PubMed ID: 27503659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections.
    Heo YA
    Drugs; 2021 Feb; 81(3):377-388. PubMed ID: 33630278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections.
    Smith JR; Rybak JM; Claeys KC
    Pharmacotherapy; 2020 Apr; 40(4):343-356. PubMed ID: 32060929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating imipenem + cilastatin + relebactam for the treatment of complicated urinary tract infections.
    Kuiper SG; Leegwater E; Wilms EB; van Nieuwkoop C
    Expert Opin Pharmacother; 2020 Oct; 21(15):1805-1811. PubMed ID: 32820669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital-acquired/ventilator-associated bacterial pneumonia.
    Patel M; Bellanti F; Daryani NM; Noormohamed N; Hilbert DW; Young K; Kulkarni P; Copalu W; Gheyas F; Rizk ML
    Clin Transl Sci; 2022 Feb; 15(2):396-408. PubMed ID: 34704389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants.
    Wang X; Liu N; Wei Y; Zhang S; Li H; Yan B; Patel M; Wang H; Boundy KE; Colon-Gonzalez F; Zang Y; Zhao X
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33288637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imipenem/cilastatin sodium/relebactam fixed combination to treat urinary infections and complicated intra-abdominal bacterial infections.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2020 Apr; 56(4):241-255. PubMed ID: 32309820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development.
    Sy SKB; Zhuang L; Sy S; Derendorf H
    Clin Pharmacokinet; 2019 May; 58(5):545-564. PubMed ID: 30097887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data.
    Yoshizawa K; Ikawa K; Ikeda K; Kumon H; Ohge H; Morikawa N
    Int J Antimicrob Agents; 2012 Nov; 40(5):427-33. PubMed ID: 22877766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants.
    Rhee EG; Rizk ML; Calder N; Nefliu M; Warrington SJ; Schwartz MS; Mangin E; Boundy K; Bhagunde P; Colon-Gonzalez F; Jumes P; Liu Y; Butterton JR
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin.
    Bhagunde P; Colon-Gonzalez F; Liu Y; Wu J; Xu SS; Garrett G; Jumes P; Lasseter K; Marbury T; Rizk ML; Lala M; Rhee EG; Butterton JR; Boundy K
    Br J Clin Pharmacol; 2020 May; 86(5):944-957. PubMed ID: 31856304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and Monte Carlo Dosing Simulations of Imipenem in Critically Ill Patients with Life-Threatening Severe Infections During Support with Extracorporeal Membrane Oxygenation.
    Jaruratanasirikul S; Vattanavanit V; Wongpoowarak W; Nawakitrangsan M; Samaeng M
    Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):735-747. PubMed ID: 32886347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simplification of Imipenem Dosing by Removal of Weight-Based Adjustments.
    Lala M; Brown M; Kantesaria B; Walker B; Paschke A; Rizk ML
    J Clin Pharmacol; 2019 May; 59(5):646-653. PubMed ID: 30536420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.